DANCAN — Dancann Pharma A/S Income Statement
0.000.00%
Last trade - 00:00- DKK2.28m
- -DKK1.19m
- DKK7.76m
Annual income statement for Dancann Pharma A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | DAS | DAS | DAS | DAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.874 | 5.71 | 6.07 | 7.76 |
| Cost of Revenue | |||||
| Gross Profit | — | 1.69 | 3.85 | 3.04 | 3.81 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.87 | 15.4 | 22.1 | 66.2 | 14.5 |
| Operating Profit | -5.87 | -14.5 | -16.4 | -60.1 | -6.69 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.99 | -15.2 | -18.3 | -62.2 | -7.93 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.25 | -11.8 | -16.1 | -62.3 | -7.93 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.25 | -11.8 | -16.1 | -62.3 | -7.93 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.25 | -11.8 | -16.1 | -62.3 | -7.93 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -50 | -105 | -63.3 | -63.9 | -1.99 |
| Dividends per Share |